ArticleTranslational oncology2025
FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mining and experimental validation of machine learning-based immune-related diagnostic biomarkers for hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Effects of type 3 and neutrophilic inflammation on type 2 chronic rhinosinusitis with nasal polyps.The Journal of allergy and clinical immunology · 2026Article
- Yiqihuoxue formula improves atherosclerosis by regulating macrophage polarization associated with enhanced STAT6/PPARγ pathway.Frontiers in cardiovascular medicine · 2026Article
- A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common subtype of primary liver cancer is hepatocellular carcinoma (HCC), which accounts for about 90 % of primary liver cancers. Tumor microenvironment (TME) plays important roles in HCC development. TME coexists and interacts with various immune cells. Macrophages are the main components of immune cells in TME. However, the specific mechanism of macrophages in HCC development is not fully understood. We conducted a preliminary study on the gene expression differences between HCC macrophages and paracancer macrophages by single-cell sequencing. Results demonstrated that FCGR2A was highly expressed in liver cancer tissues, and FCGR2A was mainly expressed in M2 macrophages in cancer tissues. The expression level of FCGR2A was correlated with extrahepatic metastasis, maximum tumor diameter, CNLC stage, satellite nodule, and differentiation degree. High FCGR2A expression predicts worse overall survival (OS) and progression-free survival (PFS) in HCC patients. In vivo experiments have verified that both FCGR2A mRNA and protein levels are markedly upregulated in M2 macrophages. Transfection of FCGR2A has been demonstrated to drive the polarization of M2 macrophages through augmenting IL-4 secretion. Further experiments showed that FCGR2A regulated and activated the IL-4/JAK/STAT6 pathway. Inhibition of JAK/STAT6 signaling pathway is capable of counteracting the promoting influence of FCGR2A-induced M2 macrophages on HCC cell proliferation. What's more,macrophages with high FCGR2A expression showed immunosuppressive influence on NK and T cells viabilities and killing activities on HCC tumor cells. Our findings reveal a crucial FCGR2A /IL-4/JAK/STAT6 axis for M2 polarization and provide a rationale for therapeutics of macrophages targeting HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.